Clinical Trial Evidence Introduction Therapeutic Recommendations Therapeutic Recommendations in Groups B and D Bronchodilators in Stable COPD ICS in Stable COPD COPD Potential AEs of ICS Treatment ID: 778491
Download The PPT/PDF document "Personalizing COPD Therapy According to ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Personalizing COPD Therapy According to Recent Clinical Trial Evidence
Slide2Slide3Introduction
Slide4Therapeutic Recommendations
Slide5Therapeutic Recommendations in Groups B and D
Slide6Bronchodilators in Stable COPD
Slide7ICS in Stable COPD
Slide8COPD Potential AEs of ICS Treatment
Slide9Slide10Diabetes Onset on ICS
Slide11FLAME: IND/GLY vs SFC for COPD Exacerbations in High-Risk Population
Slide12FLAME: Primary Endpoint Noninferiority and Superiority for IND/GLY vs SFC
Slide13FLAME: Effect of IND/GLY on Time to First Exacerbation Compared With SFC
Slide14Triple StudiesComparisons
Slide15Triple StudiesComparisons (cont)
Slide16TRIBUTELABA/LAMA/ICS vs LABA/LAMA
Slide17TRIBUTERate of Moderate and Severe Exacerbations
Slide18TRIBUTE Main AEs and Serious AEs
Slide19IMPACT
LABA/LAMA/ICS vs LABA/ICS + LABA/LAMA
Slide20Evolution of Exacerbations
Slide21IMPACTEffect on Pneumonia
Slide22SUNSET Trial Design
Slide23Primary Endpoint: Change From Baseline in Postdose Trough FEV1 (Noninferiority Analysis)
Slide24SUNSET Rate of COPD Exacerbations During the 26-Week Treatment Period
Slide25Exacerbation Rate Analysis and Blood Eosinophil Levels
Slide26WISDOM: ICS Withdrawal Did Not Increase the Exacerbations in Patients With Severe COPD
Slide27WISDOM Post-Hoc AnalysisICS Withdrawal and Exacerbation Risk
Slide28DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations
Slide29DYNAGITO Study Design: Tiotropium and Olodaterol in the Prevention of COPD Exacerbations (cont)
Slide30GOLD Recommendations in the Group D
Slide31Airway Obstruction and Lung Hyperinflation in COPD Are Linked to an Impaired Left Ventricular Diastolic Filling
Slide32Interaction of Heart and Lung in COPD Hyperinflation vs Diastolic Filling
Slide33CLAIM Study Design
Slide34CLAIM Study Results
Slide35Lung Deflation With Indacaterol/Glycopyrronium Improves Pulmonary Microvascular Blood Flow
Slide36Concluding Remarks
Slide37